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Objectives: This study aimed to evaluate cost-related trends associ-
ated with the management of critical limb ischemia (CLI) in a national
United States sample.
Methods: All patients with a primary diagnosis code of CLI were
identiﬁed from the 2001 to 2011 National Inpatient Sample. Demo-
graphics, CLI management, comorbidities, complications (bleeding, surgi-
cal site infection [SSI]), length of stay, and median in-hospital costs were
reviewed. Statistical analysis was completed using descriptive statistics, the
Student t-test, and the Fisher exact test. Costs are reported in 2011 United
States dollars corrected using the Consumer Price Index.
Results: From 2001 to 2011, 92,160 patients underwent open or
endovascular management for CLI. Table I depicts the incidence and
complications of CLI patients managed with endovascular versus open
techniques from 2001 to 2011. Overall, costs to treat CLI increased by
63%, from $12,560 in 2001 to $20,517 in 2011 (P < .001 in trend anal-
ysis). Endovascular interventions were 20% more expensive compared with
open surgery ($19,566 vs $16,337; P < .001). Age, gender, and insurance
status did not affect the cost of care. From 2001 to 2011, increases were
documented in the number of patient comorbidities (from 7.56 to 12.40),
procedures (from 3.46 to 4.96), and percentage of endovascular cases
(from 13.4% to 27.4%), accounting for a 6% annual increase in the total
cost even with a decreased mean length of stay (8.5 to 6.5 days). Patients
with SSI (1276 [1.4%]) had total costs 83% greater than patients without
SSI ($30,949 vs $16,939; P < .001), and patients who developed
bleeding complications (4131 [4.5%]) and required a return to the oper-
ating room had total costs 41% greater than nonbleeding patients
($23,779 vs $16,821; P < .001). Overall, there was a 32% decrease in
SSI but unchanged rates of bleeding complications in this time period.
Conclusions: The cost of CLI has increased signiﬁcantly during the
last decade. An increasing trend is seen in the number of patient comorbid-
ities and in the number of CLI patients managed endovascularly. The costs
of treating preventable complications, including SSI and bleeding, signiﬁ-
cantly drive the overall cost of managing patients with CLI.
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M. Malinowski: None; C. J. Lee: None.Table. The incidence and costs of complications in critical limb ischemia patien
Year 2001 2002 2003 2004 2005
Open procedure
No. 7343 6995 6301 6321 6258
SSI 119 141 103 118 103
Bleeding 326 304 265 288 249
Cost ($) 12,490 13,576 14,702 15,236 15,933
Endovascular procedure
No. 1137 1176 1442 1771 1873
SSI 13 15 13 19 15
Bleeding 58 78 75 109 108
Cost ($) 13,097 13,688 15,694 17,277 17,292
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Objectives: Percutaneous endovascular aortic aneurysm repair
(PEVAR) through the common femoral artery (CFA) is a safe alternative
to traditional open CFA exposure. Technical success is reduced if the
CFA is an inappropriate percutaneous target. During the last 5 years we
have routinely used the superﬁcial femoral artery (SFA) for EVAR cutdown
and have noted that the SFA may be a superior target for percutaneous ac-
cess in a minority of patients. Despite this, its use for PEVAR has not been
reported to date. We present a case series of 10 patients who underwent
PEVAR that used one or both SFAs.
Methods: We reviewed all PEVAR procedures at our two institutions
since October 2012, identifying all patients in whom one or both SFAs were
used for endograft delivery. We reviewed intraoperative ﬁndings and the last
available follow-up computed tomography scans to assess indication, tech-
nical success, and long-term patency.
Results: Of 79 PEVAR procedures that were recorded, 10
involved one or both SFAs. In total, 13 SFAs were used: six for the
introduction of the main body component (size range 18F-20F) and
seven for the introduction of the limb (14F-16F) (Table). There were
two failures, both of which involved a limb component. One failure,
in a somewhat diseased artery, was due to vessel occlusion at procedure
completion. The other had an active bleed at the time of the initial
sheath insertion that required cutdown. In the remaining six main
body procedures and ﬁve limb introduction procedures, intraoperative
completion duplex imaging conﬁrmed successful closure and vessel
patency. All patients maintained patency of the SFA at latest follow-
up computed tomography scan (range, 1-13 months; median, 8
months). Indications for use of the SFA instead of CFA included
obesity (depth to CFA >3.5-4.0 cm from the skin), CFA anterior
wall calciﬁcation or mural thrombus, scarring from previous CFA sur-
gery, tortuous iliac arteries (easier to advance closure device an
adequate length when starting more distally), and high bifurcation of
the CFA.
Conclusions: This preliminary evaluation suggests that the SFA may
be used for up to 20F access with PEVAR when the CFA is judged inap-
propriate. Completion duplex is recommended to assess patency. Further
studies will be required to conﬁrm these ﬁndings.
Author Disclosures: R. Faizer: Honoraria from Medtronic Inc for
speaking and teaching. A. Aaron: None; H. Trieu: None; S. Levin:
None; A. Messelt: None; M. Rosenberg: None; S. Santilli: None.ts treated with endovascular or open techniques from 2001 to 2011
2006 2007 2008 2009 2010 2011
7052 6960 7676 7035 6843 7700
101 121 114 102 89 100
278 296 368 280 297 323
15,998 16,928 18,047 18,313 18,874 19,616
2208 2607 2978 2657 2643 2899
26 13 13 18 18 25
127 143 130 111 121 143
18,464 19,874 20,406 22,716 23,082 22,906
1099
Table. Results and indications for percutaneous endovascular aortic aneurysm repair (PEVAR) utilizing superﬁcial femoral artery (SFA)
Patient MAIN LIMB Indication for SFA Complication
Follow-up CT
results
Time to
follow-up
(months)
Device
caliber
R (F)
Device
caliber
L (F)
1 R SFA L SFA Calciﬁed bilateral CFAs, morbid obesity None Patent R & L SFA 1 18 14
2 R SFA Calciﬁed bilateral CFAs None Patent R SFA 2 18
3 R SFA Morbid obesity, prior groin infections None Patent R SFA 1 16
4 L SFA High CPA bifurcation None Patent L SFA 8 14
5 L SFA Morbid obesity Suture
Positioning bleed
Patent L SFA 8 20
6 L SFA R SFA Morbid obesity SFA thrombus Patent R & L SFA 8 14 20
7 L SFA R SFA Tortuous iliac arteries None Patent R & L SFA 1 16 18
8 R SFA Signiﬁcant anterior wall thrombus of R CFA None Patent R SFA 12 14
9 R SFA Calciﬁed R CFA None Patent R SFA 13 14
10 L SFA Scarring/visible repair site of L CFA None Patent L SFA 12 18
CFA, Common femoral artery.
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Objectives: The Magellan Robot catheter (Hansen Medical, Moun-
tain View, Calif) recently received clearance by the Food and Drug Admin-
istration for use on peripheral vessels. Our institution acquired the system in
January 2014. We report our institution’s initial experience with the Magel-
lan system.
Methods: We retrospectively reviewed the records for all patients
who underwent Magellan-assisted endovascular procedures between
January 28, 2014, and April 26, 2014. Prior to the ﬁrst procedure, the
attending surgeon and staff underwent simulator and model training
and certiﬁcation for the Magellan system. Patient demographics, comor-
bidities, and operative statistics were recorded for analysis in accordance
with IRB guidelines.
Results: A total of 14 patients (64% male) underwent 15 Magel-
lan-assisted therapies. The average age of our patients was 68 years.
Four patients had undergone previous open or endovascular procedures
on the treated extremity. Eight procedures involved atherosclerotic
occlusive disease of the legs, 3 aortic aneurysm repairs, 2 visceral steno-
ses, 1 subclavian artery occlusion, and 1 right innominate vein occlu-
sion. One case was aborted due to small iliac and femoral artery
access. Two cases were unsuccessful due to failure to cross a venous
chronic total occlusion and inability to advance the robotic sheath
into the innominate artery. Operative statistics included an average
blood loss of 125 6 114 mL, 57 6 42 mL contrast use, and 30 6
14 minutes of ﬂuoroscopy time, with an average radiation exposure
of 4866 6 6639 mGy.
Conclusions: The overall success rate for the Magellan system was
87%. There was a deﬁnite learning curve, as evidenced by our longer ﬂuo-
roscopy times. However, the ﬂexibility of the leader catheter and ability
to turn 180o made it possible to treat visceral arteries from the groin. We
also found an advantage with the robotic catheter in crossing the iliac bifur-
cation even in patients with acute angulation or prior stenting. As more cen-
ters acquire the Magellan system, we feel participation in the ROVER
robotic catheter registry will play a vital role in better deﬁning the proper
use of this new technology.
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Access Site Complications Are Commonly Found on Femoral Artery
Duplex Ultrasound and Associated With Age and Manual Pressure
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Objectives: A duplex ultrasound study (DUS) is often the ﬁrst test to
evaluate the femoral vessels for complication after percutaneous femoral ac-
cess performed for cardiac and peripheral vascular (PV) diagnostic and inter-
ventional procedures. This retrospective study examined all patients over a
2-year period who underwent a DUS for a suspected access site complica-
tion after femoral access at our institution to try to deﬁne risk factors for
developing a complication.
Methods: The hospital peripheral vascular laboratory database was
reviewed, and all patients who underwent femoral DUS from January2010 to December 2011 were identiﬁed. Patients were excluded if they
did not have a femoral access procedure performed at our institution for
vascular or cardiac diagnostic/interventional purposes #1 month prior to
the DUS. Hospital records were reviewed, and demographics, procedural
details, and complications were recorded. Completion angiograms were
graded by a single investigator for location of puncture, femoral disease,
and size of the femoral artery.
Results: A total of 18,167 cardiac and PV procedures were performed
during the study period. A total of 222 patients had a DUS and were
divided into those with an access site complication (group A, 103 patients
[46.4%]) and those without (group B, 119 patients [53.6%]). Gender and
body mass index were similar between the groups; however, the group A
patients were signiﬁcantly older than the group B patients (62.4 vs 56.9
years; P ¼ .003). The most common complications identiﬁed on DUS
were hematoma (n ¼ 55 [53.4%]) and pseudoaneurysm (n ¼ 33
[32.0%]). A closure device was more commonly used in group B patients
(71 vs 49 patients; P ¼ .007). No single femoral anatomic feature on
completion angiogram was more commonly associated with sustaining a
complication.
Conclusions: DUS, performed for evaluation of the femoral access
site after cardiac or PV procedures, has a high yield for complications. He-
matoma is the most common complication, followed by pseudoaneurysm.
Older age and manual pressure for closure were associated with access site
complication.
Author Disclosures: L. L. Masterson: None; T. Corby: None; M.
Haurani: None; L. Yu: None; J. Starr: None.
Stent Fractures and Restenosis Rates Following Carotid Artery
Stenting
Mohammad Sarhan, MD, Sherry L. Cavanagh, MD, Robert G.
Molnar, MD. Vascular Surgery, Michigan Vascular Center/Michigan
State University/McLaren Region Medical Center, Flint, Mich
Objectives: Carotid artery stenting (CAS) is being performed more
frequently for carotid occlusive disease and has been approved for use in
high-risk patients. There have been reports of carotid stent fractures, but
prospective data are limited. To better understand the incidence of CAS
fracture and risk of restenosis, we prospectively evaluated CAS patients for
fracture and restenosis.
Methods: Patients who underwent CAS between January 2002 and
January 2012 were prospectively evaluated for stent fractures by anteropos-
terior and lateral cervical x-ray imaging and for restenosis by duplex ultra-
sound imaging at 1 month, 6 months, and 1 year. The x-ray images were
independently reviewed by two surgeons and two radiologists for the ﬁrst
part of the study and by three independent surgeons in the later part to
assess for stent fractures. The fracture incidence was then calculated as a per-
centage of the study population. Carotid duplex results were correlated to
those with and without stent fractures.
Results: During the study period, 400 stents were placed. A total of
143 patients, with 163 stents, agreed to participate in the study. Fractures
were found in 11 of the 163 stents (6%). Fractures were only counted if
there was unanimous agreement by the reviewers, and possible fractures
were not considered. Of the 11 with stent fractures identiﬁed, one patient
(9%) had a restenosis of 50% to 60% at 6 months and 1 year. Restenosis
occurred in eight of 152 (5%) without stent fractures, two of them were se-
vere (>80%) and the remaining six were <50%.
